Home » Topics » BioWorld Science

BioWorld Science
RSS

Merck researchers describe new protein kinase inhibitors and their use

June 21, 2004

Merck scientists develop new NO-releasing COX-2 inhibitors

June 21, 2004

Guilford patent covers new DPPIV inhibitors and their therapeutic use

June 21, 2004

New bone or tissue-selective SARMs under study at Merck

June 21, 2004

Novel inhibitors of Src kinases developed at Roche

June 21, 2004

Levitra enters Japanese market

June 21, 2004

Results from confirmatory phase II study of Aquavan

June 21, 2004

New phase II trial studies talabostat for advanced metastatic melanoma

June 21, 2004

Full enrollment in phase III Virulizin trial

June 21, 2004

Fast track designation for BAL-5788 in hospital-acquired pneumonia

June 21, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
Coreterra Therapeutics patents agents for schizophrenia
BioWorld Science
Work at Coreterra Therapeutics Inc. has led to the discovery of new thienyl compounds intended for potential use in the treatment of schizophrenia.